Nurix Therapeutics (NRIX) announced the appointment of Roger Dansey, M.D., to its board of directors. Dr. Dansey previously served as Chief Development Officer and Chief Oncology Officer of Pfizer Oncology (PFE) and as Chief Medical Officer and interim Chief Executive Officer of Seagen (SGEN).
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Nurix Therapeutics announces presentation of new data on NX-1607
- Promising Data from Nurix Therapeutics’ Bexobrutideg Supports Buy Rating
- Nurix Therapeutics’ Bexodeg: Promising Efficacy and Safety Profile Drive Buy Rating
- Nurix Therapeutics price target lowered to $28 from $33 at H.C. Wainwright
- Nurix Therapeutics’ NX-1607 Study: A Potential Game-Changer in Cancer Treatment